Literature DB >> 11830505

Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab.

Stuart L Goldberg1, Andrew L Pecora, Robert S Alter, Mark S Kroll, Scott D Rowley, Stanley E Waintraub, Kavita Imrit, Robert A Preti.   

Abstract

Efforts to reduce relapse of non-Hodgkin lymphoma after autologous transplantation have included ex vivo stem cell selection and/or peritransplantation immunotherapy. The late infectious and immunologic consequences of these maneuvers are not well understood, although an increase in early cytomegaloviral disease after CD34(+) stem cell selection and an alteration in immunoglobulin and T-cell recovery after peritransplantation rituximab has been noted. We report the first 2 cases of progressive multifocal leukoencephalopathy caused by JC papovavirus after autologous peripheral blood stem cell transplantation and a case each of cytomegalovirus retinitis and pneumonitis. All 4 patients experienced significant impairment of CD4 T-cell recovery, placing them at risk for these unusual viral infections. The clustering of cases is concerning because all occurred shortly after the introduction of peritransplantation rituximab into treatment protocols (4 of 62 immunotherapy recipients compared with 0 of 276 without; z = 3.595; P <.001), although a direct association with this CD20 B-cell-directed therapy remains speculative.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11830505     DOI: 10.1182/blood.v99.4.1486

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  42 in total

Review 1.  Does rituximab increase the incidence of infectious complications? A narrative review.

Authors:  Theodoros Kelesidis; George Daikos; Dimitrios Boumpas; Sotirios Tsiodras
Journal:  Int J Infect Dis       Date:  2010-11-11       Impact factor: 3.623

2.  Cytomegalovirus gastritis after rituximab treatment in a non-Hodgkn's lymphoma patient.

Authors:  Ugur Unluturk; Sercan Aksoy; Ozlem Yonem; Yusuf Bayraktar; Gulten Tekuzman
Journal:  World J Gastroenterol       Date:  2006-03-28       Impact factor: 5.742

3.  Prolonged reactivation of cytomegalovirus infection following successful rituximab therapy for Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder.

Authors:  Makoto Hirokawa; Yoshinari Kawabata; Naohito Fujishima; Tomoko Yoshioka; Ken-ichi Sawada
Journal:  Int J Hematol       Date:  2007-10       Impact factor: 2.490

Review 4.  Neurologic complications of antitumor antibody therapies.

Authors:  Teri N Kreisl
Journal:  Curr Neurol Neurosci Rep       Date:  2008-05       Impact factor: 5.081

5.  Inclusion of rituximab in treatment protocols for non-Hodgkin's lymphomas and risk for progressive multifocal leukoencephalopathy.

Authors:  Marco Tuccori; Daniele Focosi; Corrado Blandizzi; Matteo Pelosini; Sabrina Montagnani; Fabrizio Maggi; Mauro Pistello; Luca Antonioli; Matteo Fornai; Pasquale Pepe; Giuseppe Rossi; Mario Petrini
Journal:  Oncologist       Date:  2010-11-01

6.  Progressive multifocal leukoencephalopathy in transplant recipients.

Authors:  Farrah J Mateen; RajaNandini Muralidharan; Marco Carone; Diederik van de Beek; Daniel M Harrison; Allen J Aksamit; Mary S Gould; David B Clifford; Avindra Nath
Journal:  Ann Neurol       Date:  2011-08       Impact factor: 10.422

Review 7.  Progressive multifocal leukoencephalopathy in a patient with B-cell lymphoma during rituximab-containing chemotherapy: case report and review of the literature.

Authors:  Hiroki Yokoyama; Takashi Watanabe; Dai Maruyama; Sung-Won Kim; Yukio Kobayashi; Kensei Tobinai
Journal:  Int J Hematol       Date:  2008-10-15       Impact factor: 2.490

Review 8.  [Targeting B cells in multiple sclerosis. Current concepts and strategies].

Authors:  T Menge; H-C Büdingen; M C Dalakas; B C Kieseier; H-P Hartung
Journal:  Nervenarzt       Date:  2009-02       Impact factor: 1.214

9.  Rituximab in the treatment of non-Hodgkin's lymphoma.

Authors:  Beate Hauptrock; Georg Hess
Journal:  Biologics       Date:  2008-12

10.  First Isolation of West Nile virus from a patient with encephalitis in the United States.

Authors:  Cinnia Huang; Brett Slater; Robert Rudd; Nandakishore Parchuri; Rene Hull; Michelle Dupuis; Alexander Hindenburg
Journal:  Emerg Infect Dis       Date:  2002-12       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.